In a strategic move to capture a significant share of the Canadian healthcare market, the American telehealth company Hims & Hers Health, Inc. has officially announced its expansion into Canada. The entry is facilitated by the acquisition of Livewell, a domestic online platform specializing in weight loss and telehealth services.
Timing the Market with Generic Semaglutide
The company's planned launch next year is strategically synchronized with a pivotal shift in the pharmaceutical landscape. For the first time globally, a generic version of the drug semaglutide is anticipated to become available. Semaglutide, famously marketed under the brand names Ozempic for type 2 diabetes and Wegovy for weight management, has seen explosive demand as an effective anti-obesity medication.
This opportunity arose after Danish pharmaceutical leader Novo Nordisk inadvertently allowed its Canadian patent for semaglutide to expire. According to the Canadian Patent Database, the patent, initially issued in 2013, is now "expired and beyond the period of reversal." Reports indicate the company last paid the modest annual maintenance fee of $250 in 2018, forfeiting protection years ahead of its U.S. patent, which holds until at least 2032.
Addressing a Critical Public Health Need
Hims & Hers frames its Canadian foray as a direct response to a pressing national health issue. The company cites data showing that almost two-thirds of adults in Canada are overweight or living with obesity. Currently, patients seeking branded semaglutide can face costs exceeding $200 per month without integrated clinical support, a significant barrier to access.
Andrew Dudum, co-founder and CEO of Hims & Hers, stated the expansion is "a direct response to critical public health needs, particularly around the obesity crisis." The company promises its generic version will be offered at a "significant discount" to current branded prices, with costs expected to decrease further over time.
Building a Canadian Leadership Team
To spearhead its operations, Hims & Hers is establishing a local Canadian team. Austin Kouri, formerly an executive at DoorDash, will take the helm as General Manager of Hims & Hers Canada. He will work alongside Dr. Sandy Van, a prominent obesity physician who will serve as the Chief Medical Officer for the Canadian branch.
The founders of the acquired company, Livewell, Antoine Arbour and Patrick Duffy, will also join the Canadian leadership team. Arbour expressed that joining Hims & Hers represents "a vital step forward" in democratizing access to essential care for millions of Canadians nationwide.
While the market potential is substantial, it's important to note that as of early December 2025, no generic version of semaglutide has yet received approval from Health Canada. The success of Hims & Hers' strategy hinges on navigating the regulatory pathway and bringing an approved, affordable alternative to a population in clear need of more accessible weight management solutions.
